Acalabrutinib and Ribociclib: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Ribociclib inhibits CYP3A to a moderate or strong degree depending on the regimen, potentially increasing the partner medicine’s exposure.
Clinical significance and safety
The interaction between Acalabrutinib and Ribociclib depends on the ribociclib regimen and on the other anticancer medicine’s product information. The rules for a strong inhibitor must not automatically be applied to a moderate inhibitor. Strong inhibition may require avoidance, interruption or specialist adjustment; moderate inhibition still needs the partner-specific monitoring or adjustment described below. The oncology team must make these decisions. For acalabrutinib, moderate inhibition requires close monitoring without an automatic dose adjustment under the EMA label; a strong short-term inhibitor can require specialist-planned interruption.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.